JP6602863B2 - ブプロピオンまたは関連組成物およびデキストロメトルファンを含む医薬組成物 - Google Patents

ブプロピオンまたは関連組成物およびデキストロメトルファンを含む医薬組成物 Download PDF

Info

Publication number
JP6602863B2
JP6602863B2 JP2017527254A JP2017527254A JP6602863B2 JP 6602863 B2 JP6602863 B2 JP 6602863B2 JP 2017527254 A JP2017527254 A JP 2017527254A JP 2017527254 A JP2017527254 A JP 2017527254A JP 6602863 B2 JP6602863 B2 JP 6602863B2
Authority
JP
Japan
Prior art keywords
dextromethorphan
bupropion
day
administered
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017527254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535563A (ja
Inventor
タビュトー、ヘリオット
Original Assignee
アンテシップ バイオベンチャーズ トゥー エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56014366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6602863(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/550,618 external-priority patent/US9198905B2/en
Priority claimed from US14/602,177 external-priority patent/US9402843B2/en
Application filed by アンテシップ バイオベンチャーズ トゥー エルエルシー filed Critical アンテシップ バイオベンチャーズ トゥー エルエルシー
Publication of JP2017535563A publication Critical patent/JP2017535563A/ja
Application granted granted Critical
Publication of JP6602863B2 publication Critical patent/JP6602863B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2017527254A 2014-11-21 2015-05-01 ブプロピオンまたは関連組成物およびデキストロメトルファンを含む医薬組成物 Active JP6602863B2 (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US14/550,618 2014-11-21
US14/550,618 US9198905B2 (en) 2013-11-05 2014-11-21 Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US14/555,085 US9238032B2 (en) 2013-11-05 2014-11-26 Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US14/554,947 US20150126542A1 (en) 2013-11-05 2014-11-26 Compositions and Methods for Increasing the Metabolic Lifetime of Dextromethorphan and Related Pharmacodynamic Effects
US14/554,988 2014-11-26
US14/554,947 2014-11-26
US14/555,085 2014-11-26
US14/554,988 US9205083B2 (en) 2013-11-05 2014-11-26 Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
US14/602,177 US9402843B2 (en) 2013-11-05 2015-01-21 Compositions and methods of using threohydroxybupropion for therapeutic purposes
US14/602,177 2015-01-21
US14/604,397 2015-01-23
US14/604,397 US9168234B2 (en) 2013-11-05 2015-01-23 Bupropion as a modulator of drug activity
US14/617,624 2015-02-09
US14/617,624 US9486450B2 (en) 2013-11-05 2015-02-09 Hydroxybupropion and related compounds as modulators of drug plasma levels
US14/628,062 2015-02-20
US14/628,062 US9402844B2 (en) 2013-11-05 2015-02-20 Methods of modulating drug plasma levels using erythrohydroxybupropion
PCT/US2015/028901 WO2016081027A1 (en) 2014-11-21 2015-05-01 Methods of modulating drug plasma levels using erythrohydroxybupropion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019185676A Division JP6842129B2 (ja) 2014-11-21 2019-10-09 ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法

Publications (2)

Publication Number Publication Date
JP2017535563A JP2017535563A (ja) 2017-11-30
JP6602863B2 true JP6602863B2 (ja) 2019-11-06

Family

ID=56014366

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017527254A Active JP6602863B2 (ja) 2014-11-21 2015-05-01 ブプロピオンまたは関連組成物およびデキストロメトルファンを含む医薬組成物
JP2019185676A Active JP6842129B2 (ja) 2014-11-21 2019-10-09 ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法
JP2021016211A Active JP7226839B2 (ja) 2014-11-21 2021-02-04 ブプロピオンおよびデキストロメトルファンを含む組成物
JP2023014583A Pending JP2023041862A (ja) 2014-11-21 2023-02-02 ニコチン中毒の治療が必要な人の治療のための医薬品の製造における、ブプロピオンまたはその薬学的に許容される塩と、デキストロメトルファンまたはその薬学的に許容される塩との組み合わせの使用
JP2025077089A Pending JP2025105965A (ja) 2014-11-21 2025-05-07 ブプロピオンおよびデキストロメトルファンを含む剤形

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019185676A Active JP6842129B2 (ja) 2014-11-21 2019-10-09 ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法
JP2021016211A Active JP7226839B2 (ja) 2014-11-21 2021-02-04 ブプロピオンおよびデキストロメトルファンを含む組成物
JP2023014583A Pending JP2023041862A (ja) 2014-11-21 2023-02-02 ニコチン中毒の治療が必要な人の治療のための医薬品の製造における、ブプロピオンまたはその薬学的に許容される塩と、デキストロメトルファンまたはその薬学的に許容される塩との組み合わせの使用
JP2025077089A Pending JP2025105965A (ja) 2014-11-21 2025-05-07 ブプロピオンおよびデキストロメトルファンを含む剤形

Country Status (22)

Country Link
EP (2) EP3220909B2 (https=)
JP (5) JP6602863B2 (https=)
KR (7) KR101931896B1 (https=)
CN (2) CN111297860A (https=)
AU (4) AU2015350559C1 (https=)
CA (3) CA3232022A1 (https=)
CY (1) CY1123571T1 (https=)
DK (1) DK3220909T3 (https=)
ES (1) ES2835304T3 (https=)
HR (1) HRP20201855T1 (https=)
HU (1) HUE052609T2 (https=)
IL (4) IL297349B2 (https=)
LT (1) LT3220909T (https=)
MX (3) MX2017006653A (https=)
MY (1) MY189466A (https=)
PL (1) PL3220909T3 (https=)
PT (1) PT3220909T (https=)
RS (1) RS61113B1 (https=)
SG (2) SG11201704066VA (https=)
SI (1) SI3220909T1 (https=)
SM (1) SMT202000639T1 (https=)
WO (1) WO2016081027A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11576909B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11229640B2 (en) 2013-11-05 2022-01-25 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11576877B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as modulator of drug activity
US11419867B2 (en) 2013-11-05 2022-08-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291665B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11590124B2 (en) 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11344544B2 (en) 2013-11-05 2022-05-31 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11357744B2 (en) 2013-11-05 2022-06-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11524007B2 (en) 2013-11-05 2022-12-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285118B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11497721B2 (en) 2013-11-05 2022-11-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426370B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11596627B2 (en) 2013-11-05 2023-03-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11382874B2 (en) 2013-11-05 2022-07-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617728B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617747B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11517543B2 (en) 2013-11-05 2022-12-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571399B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11364233B2 (en) 2013-11-05 2022-06-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11207281B2 (en) 2013-11-05 2021-12-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11478468B2 (en) 2013-11-05 2022-10-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11191739B2 (en) 2013-11-05 2021-12-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571417B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541021B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20220233470A1 (en) 2013-11-05 2022-07-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11439636B1 (en) 2013-11-05 2022-09-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426401B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11197839B2 (en) 2013-11-05 2021-12-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298352B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11510918B2 (en) 2013-11-05 2022-11-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541048B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298351B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
CA3232022A1 (en) * 2014-11-21 2016-05-26 Antecip Bioventures Ii Llc Methods of modulating drug plasma levels using erythrohydroxybupropion
US12569479B2 (en) 2016-05-25 2026-03-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
SMT202600055T1 (it) * 2019-01-07 2026-03-09 Antecip Bioventures Ii Llc Combinazione di destrometorfano e bupropione per trattare la depressione in pazienti asiatici
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
EP4183391A4 (en) * 2020-07-20 2024-04-17 Shenzhen Salubris Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION AND ITS USE
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350756A (en) * 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
EP1986639A4 (en) * 2006-02-03 2010-04-28 Avanir Pharmaceuticals PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES
WO2009006194A1 (en) 2007-06-28 2009-01-08 Avanir Pharmaceuticals Pharmaceutical compositions for the treatment of involuntary emotional expression disorder
WO2012118562A1 (en) 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US20130274282A1 (en) * 2012-04-16 2013-10-17 Herriot Tabuteau Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MY179696A (en) 2013-11-05 2020-11-11 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds and dextromethorphan
US9402843B2 (en) 2013-11-05 2016-08-02 Antecip Bioventures Ii Llc Compositions and methods of using threohydroxybupropion for therapeutic purposes
US9198905B2 (en) 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
CA3232022A1 (en) 2014-11-21 2016-05-26 Antecip Bioventures Ii Llc Methods of modulating drug plasma levels using erythrohydroxybupropion

Also Published As

Publication number Publication date
MX2017006653A (es) 2017-10-31
RS61113B1 (sr) 2020-12-31
JP2020023527A (ja) 2020-02-13
JP2017535563A (ja) 2017-11-30
CN111297860A (zh) 2020-06-19
JP6842129B2 (ja) 2021-03-17
EP3220909A1 (en) 2017-09-27
KR102822654B1 (ko) 2025-06-18
AU2019201548B2 (en) 2020-11-26
HRP20201855T1 (hr) 2021-04-02
IL280905A (en) 2021-04-29
AU2015350559C1 (en) 2019-07-11
KR102253986B1 (ko) 2021-05-21
IL314982A (en) 2024-10-01
EP3220909B1 (en) 2020-09-02
MX2021001442A (es) 2023-01-05
CA3082645A1 (en) 2016-05-26
SMT202000639T1 (it) 2021-01-05
CA2968371A1 (en) 2016-05-26
WO2016081027A1 (en) 2016-05-26
AU2021200981B2 (en) 2024-06-20
ES2835304T3 (es) 2021-06-22
IL252417A0 (en) 2017-07-31
KR102640586B1 (ko) 2024-02-23
JP2023041862A (ja) 2023-03-24
JP2025105965A (ja) 2025-07-10
MX2023000320A (es) 2023-02-09
CY1123571T1 (el) 2022-03-24
PT3220909T (pt) 2020-12-07
AU2021200981A1 (en) 2021-03-11
MY189466A (en) 2022-02-15
EP3220909A4 (en) 2018-07-11
CN107205998A (zh) 2017-09-26
AU2019201548A1 (en) 2019-03-28
AU2019201548C1 (en) 2021-09-16
KR20230056795A (ko) 2023-04-27
SG11201704066VA (en) 2017-06-29
EP3220909B2 (en) 2026-02-18
KR20170088926A (ko) 2017-08-02
KR20180136003A (ko) 2018-12-21
IL252417B (en) 2021-03-25
KR20220038820A (ko) 2022-03-29
IL297349B2 (en) 2025-01-01
AU2015350559A1 (en) 2017-06-08
IL297349A (en) 2022-12-01
HUE052609T2 (hu) 2021-05-28
IL280905B (en) 2022-11-01
DK3220909T3 (da) 2020-11-23
LT3220909T (lt) 2021-01-25
JP7226839B2 (ja) 2023-02-21
KR102524253B1 (ko) 2023-04-20
HK1243323A1 (zh) 2018-07-13
CA3232022A1 (en) 2016-05-26
CA3082645C (en) 2024-04-16
SI3220909T1 (sl) 2021-01-29
IL280905B2 (en) 2023-03-01
KR20250092295A (ko) 2025-06-23
KR20240027872A (ko) 2024-03-04
AU2024219871A1 (en) 2024-10-10
CA2968371C (en) 2020-08-18
KR20210059788A (ko) 2021-05-25
JP2021066744A (ja) 2021-04-30
KR102376868B1 (ko) 2022-03-18
KR101931896B1 (ko) 2018-12-21
SG10201911873XA (en) 2020-02-27
IL297349B1 (en) 2024-09-01
EP3763372A1 (en) 2021-01-13
AU2015350559B2 (en) 2018-12-06
PL3220909T3 (pl) 2021-04-06

Similar Documents

Publication Publication Date Title
JP6602863B2 (ja) ブプロピオンまたは関連組成物およびデキストロメトルファンを含む医薬組成物
JP6605485B2 (ja) ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物
US9421176B1 (en) Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9408815B2 (en) Bupropion as a modulator of drug activity
US9168234B2 (en) Bupropion as a modulator of drug activity
JP2020023543A6 (ja) ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法
HK40030121A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190417

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191009

R150 Certificate of patent or registration of utility model

Ref document number: 6602863

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250